Breaking News

DPT Acquires Meda Pharma’s NJ Facilities

September 4, 2014

Provides 90,000 sq.-ft. with additional cold storage and larger analytical lab

DPT Laboratories has acquired Meda Pharmaceuticals’ Lakewood, NJ facilities, expanding its footprint in Lakewood with two buildings totaling 90,000 sq.-ft. of space. The acquisition provides additional cold storage and a larger analytical lab. DPT will also absorb Meda’s employees for the continued manufacture of MUSE, a urethral suppository product.
“The Meda Pharmaceuticals space allows us to meet the needs of our clients today and beyond,” said Gene Ciolfi, vice president and general manager, Lakewood site operations. “We are also in a better position to explore additional opportunities to further our capabilities from development through commercialization.”
“We look forward to transitioning Meda Pharmaceuticals’ personnel to the DPT team,” Mr. Ciolfi commented. “Their experience and continued dedication to quality complements our commitment to outstanding client service.”
DPT’s current Lakewood location is one of the organization’s established Centers of Excellence that provides aseptic processing suites and filling equipment for small-volume parenterals, ophthalmic preparations, preservative-free nasal sprays and sterile ointments.
blog comments powered by Disqus
  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • A Case for One Assay Analysis of PK and Immunogenicity in Biosimilar Research

    A Case for One Assay Analysis of PK and Immunogenicity in Biosimilar Research

    Stephanie Mowery, Sherri Rinker, Franklin Spriggs and Bo Kowalcyk , AIT Bioscience||June 2, 2015
    Moving forward clinical studies will have to include a comparative assessment of pharmacokinetics and immunogenicity to the original reference biologic drug